No Data
No Data
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics to Participate in Upcoming May Conferences
Oppenheimer Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Cuts Target Price to $12
RBC Capital Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating, Maintains Target Price $4
Piper Sandler Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Maintains Target Price $6
Piper Sandler Sticks to Its Buy Rating for Fulcrum Therapeutics (FULC)